Castrate Resistant Prostate Cancer Therapeutics Report

By www.reliablebusinessarena.com

Report Details

Report Name

Global Castrate Resistant Prostate Cancer Therapeutics Market Research Report 2024 Story

Pages

86

Price

$ 2900

Features

Castrate Resistant Prostate Cancer Therapeutics Report report is categorised based on following features:

1. Global Market Players

2. Geopolitical regions

3. Consumer Insights

4. Technological advancement

5. Historic and Future Analysis of the Market

Companies Covered

              Pfizer/Astellas (Xtandi)|||Johnson & Johnson|||AstraZeneca/Merck (Lynparza)|||Bayer|||Jiangsu Hengrui Pharmaceuticals|||CTTQ|||Sanofi|||Hansoh|||Clovis Oncology|||Zhendong Pharmaceutical            

Countries Covered

              "United States"|||"Canada"|||"Germany"|||"France"|||"UK"|||"Italy"|||"Russia"|||"China"|||"Japan"|||"South Korea"|||"India"|||"Australia"|||"Mexico"|||"Brazil"|||"Turkey"|||"Saudi Arabia"|||"UAE"            

Regions Covered

              "North America"|||"Europe"|||"Asia-Pacific"|||"Latin America"|||"Middle East & Africa"            

Prices

Single User License:

$ 2900

Multi User License:

$ 4350

Enterprise/Corporate User License:

$ 5800